Signatera is a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Learn more at natera.com/oncology
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No